Intellectual Property
IP Management
ScinoPharm Taiwan is committed to enhancing our IP management framework through improving internal processes, strategic patent planning, and risk management. These efforts aim to protect our R&D achievements and support their commercialization.By aligning our IP priorities with the development of Active Pharmaceutical Ingredients (APIs) and formulations, we position intellectual property as a key driver for raising technological barriers and strengthening market competitiveness.
Our 2025 IP objectives focus on supporting R&D innovation, accelerating time-to-market, and ensuring freedom to operate (FTO). These priorities guide the way we manage, protect, and expand our IP assets across business functions.
The 2025 IP policy and strategic objectives of ScinoPharm Taiwan were presented to the Board of Directors for review and approval in November 2024.
2025 IP Policy
Cultivating an IP Management Culture to Foster R&D Innovations
As a global supplier of oncology-related generic APIs, ScinoPharm Taiwan offers deep technical expertise in developing and producing high-barrier APIs, with a focus on small molecules and peptides. We also provide process development and clinical trial material manufacturing services to international pharmaceutical partners. To strengthen our global presence and drive sustainable growth, we are integrating our formulation business to offer more comprehensive solutions and expand partnerships with global pharmaceutical companies.
Recognizing the importance of IP in sustaining innovation and business continuity, we have established the following 2025 IP policies to guide our operations:
- Position IP as a strategic business asset, with dedicated systems for its management and application to enhance innovation and competitiveness.
- Protect R&D outcomes through a combination of patents and trade secrets while actively developing and maintaining our IP portfolio.
- Conduct thorough IP risk assessments and develop design-around strategies to avoid infringement and maintain freedom to operate.
- Foster a company-wide IP culture that encourages innovation and raises awareness of intellectual property protection.
2025 IP Objectives
Establishing an Integrated IP Strategy to Strengthen Competitiveness
We are advancing our IP management by optimizing internal workflows, reinforcing our patent strategies, and addressing potential IP risks across product development stages. These actions are intended to safeguard our R&D innovations and support their path to market. By aligning our IP priorities with both API and formulation development, we aim to enhance technical differentiation and expand market opportunities.
Our 2025 IP objectives align with key goals: fostering innovation, reducing time-to-market, and ensuring freedom to operate. The specific goals for 2025 include:
- Complete the implementation of the Taiwan Intellectual Property Management System (TIPS) and integrate it with internal systems to enhance IP portfolio planning and maintenance.
- Prioritize patent applications for 505(b)(2) drug candidates and key manufacturing technologies, in alignment with the company’s strategic roadmap.
- Strengthen collaboration between R&D and IP teams to proactively identify innovations for patent or trade secret protection, reducing the risk of third-party IP infringement.
- Design around originator patents and pursue Paragraph IV (PIV) certifications to accelerate ANDA product approvals.
- File oppositions or challenges against patents that may hinder the company’s freedom to operate.
- Promote IP culture by establishing an intranet IP knowledge hub and offering training on patents and trade secret management to raise employee awareness.
